vs
Nurix Therapeutics, Inc.（NRIX）与SOLAI Ltd（SLAI）财务数据对比。点击上方公司名可切换其他公司
Nurix Therapeutics, Inc.的季度营收约是SOLAI Ltd的1.2倍（$13.6M vs $11.0M），SOLAI Ltd净利率更高（-126.2% vs -576.1%，领先449.9%），Nurix Therapeutics, Inc.同比增速更快（2.2% vs -43.1%），SOLAI Ltd自由现金流更多（$-17.0M vs $-73.0M）
Nurix Therapeutics是一家临床阶段生物制药企业，专注于发现、开发及商业化针对癌症、免疫疾病等存在重大未满足医疗需求的新型靶向蛋白降解疗法，依托专有的E3泛素连接酶调节技术推进管线研发，与全球多家制药企业达成合作。
NRIX vs SLAI — 直观对比
营收规模更大
NRIX
是对方的1.2倍
$11.0M
营收增速更快
NRIX
高出45.3%
-43.1%
净利率更高
SLAI
高出449.9%
-576.1%
自由现金流更多
SLAI
多$56.0M
$-73.0M
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.6M | $11.0M |
| 净利润 | $-78.2M | $-13.9M |
| 毛利率 | — | 0.1% |
| 营业利润率 | -612.0% | -126.2% |
| 净利率 | -576.1% | -126.2% |
| 营收同比 | 2.2% | -43.1% |
| 净利润同比 | -33.6% | -173.4% |
| 每股收益（稀释后） | $-0.83 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NRIXSLAI
| Q4 25 | $13.6M | — | ||
| Q3 25 | $7.9M | — | ||
| Q2 25 | $44.1M | $11.0M | ||
| Q1 25 | $18.5M | — | ||
| Q4 24 | $13.3M | — | ||
| Q3 24 | $12.6M | — | ||
| Q2 24 | $12.1M | $19.4M | ||
| Q1 24 | $16.6M | — |
净利润NRIXSLAI
| Q4 25 | $-78.2M | — | ||
| Q3 25 | $-86.4M | — | ||
| Q2 25 | $-43.5M | $-13.9M | ||
| Q1 25 | $-56.4M | — | ||
| Q4 24 | $-58.5M | — | ||
| Q3 24 | $-49.0M | — | ||
| Q2 24 | $-44.5M | $18.9M | ||
| Q1 24 | $-41.5M | — |
毛利率NRIXSLAI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 52.4% | ||
| Q1 24 | — | — |
营业利润率NRIXSLAI
| Q4 25 | -612.0% | — | ||
| Q3 25 | -1157.7% | — | ||
| Q2 25 | -109.7% | -126.2% | ||
| Q1 25 | -340.7% | — | ||
| Q4 24 | -486.7% | — | ||
| Q3 24 | -433.8% | — | ||
| Q2 24 | -401.4% | -2.6% | ||
| Q1 24 | -272.6% | — |
净利率NRIXSLAI
| Q4 25 | -576.1% | — | ||
| Q3 25 | -1094.8% | — | ||
| Q2 25 | -98.7% | -126.2% | ||
| Q1 25 | -305.4% | — | ||
| Q4 24 | -440.7% | — | ||
| Q3 24 | -388.9% | — | ||
| Q2 24 | -368.4% | 97.9% | ||
| Q1 24 | -250.3% | — |
每股收益（稀释后）NRIXSLAI
| Q4 25 | $-0.83 | — | ||
| Q3 25 | $-1.03 | — | ||
| Q2 25 | $-0.52 | $-0.01 | ||
| Q1 25 | $-0.67 | — | ||
| Q4 24 | $-0.74 | — | ||
| Q3 24 | $-0.67 | — | ||
| Q2 24 | $-0.71 | $0.02 | ||
| Q1 24 | $-0.76 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $247.0M | $1.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $538.7M | $43.8M |
| 总资产 | $688.1M | $69.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NRIXSLAI
| Q4 25 | $247.0M | — | ||
| Q3 25 | $78.4M | — | ||
| Q2 25 | $84.3M | $1.2M | ||
| Q1 25 | $75.9M | — | ||
| Q4 24 | $110.0M | — | ||
| Q3 24 | $99.0M | — | ||
| Q2 24 | $116.8M | $2.3M | ||
| Q1 24 | $49.8M | — |
股东权益NRIXSLAI
| Q4 25 | $538.7M | — | ||
| Q3 25 | $372.3M | — | ||
| Q2 25 | $447.6M | $43.8M | ||
| Q1 25 | $480.9M | — | ||
| Q4 24 | $527.0M | — | ||
| Q3 24 | $376.9M | — | ||
| Q2 24 | $370.7M | $45.9M | ||
| Q1 24 | $168.7M | — |
总资产NRIXSLAI
| Q4 25 | $688.1M | — | ||
| Q3 25 | $522.5M | — | ||
| Q2 25 | $591.6M | $69.1M | ||
| Q1 25 | $615.0M | — | ||
| Q4 24 | $669.3M | — | ||
| Q3 24 | $513.6M | — | ||
| Q2 24 | $511.0M | $63.3M | ||
| Q1 24 | $312.7M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-67.8M | $-17.0M |
| 自由现金流经营现金流 - 资本支出 | $-73.0M | $-17.0M |
| 自由现金流率自由现金流/营收 | -537.4% | -154.2% |
| 资本支出强度资本支出/营收 | 37.8% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-263.5M | — |
8季度趋势，按日历期对齐
经营现金流NRIXSLAI
| Q4 25 | $-67.8M | — | ||
| Q3 25 | $-57.4M | — | ||
| Q2 25 | $-63.2M | $-17.0M | ||
| Q1 25 | $-61.1M | — | ||
| Q4 24 | $-48.8M | — | ||
| Q3 24 | $-42.2M | — | ||
| Q2 24 | $-39.7M | $-12.1M | ||
| Q1 24 | $-42.0M | — |
自由现金流NRIXSLAI
| Q4 25 | $-73.0M | — | ||
| Q3 25 | $-60.1M | — | ||
| Q2 25 | $-65.8M | $-17.0M | ||
| Q1 25 | $-64.6M | — | ||
| Q4 24 | $-50.9M | — | ||
| Q3 24 | $-44.5M | — | ||
| Q2 24 | $-41.6M | — | ||
| Q1 24 | $-44.8M | — |
自由现金流率NRIXSLAI
| Q4 25 | -537.4% | — | ||
| Q3 25 | -761.3% | — | ||
| Q2 25 | -149.4% | -154.2% | ||
| Q1 25 | -349.9% | — | ||
| Q4 24 | -382.8% | — | ||
| Q3 24 | -353.7% | — | ||
| Q2 24 | -344.4% | — | ||
| Q1 24 | -270.3% | — |
资本支出强度NRIXSLAI
| Q4 25 | 37.8% | — | ||
| Q3 25 | 34.3% | — | ||
| Q2 25 | 6.1% | 0.0% | ||
| Q1 25 | 18.9% | — | ||
| Q4 24 | 15.8% | — | ||
| Q3 24 | 18.6% | — | ||
| Q2 24 | 16.0% | — | ||
| Q1 24 | 17.4% | — |
现金转化率NRIXSLAI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.64× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NRIX
| Pfizer | $11.9M | 88% |
| Gilead Agreement | $1.7M | 13% |
SLAI
| Data center | $6.5M | 59% |
| Cryptocurrency mining | $4.6M | 41% |
